Carisma Therapeutics Expands Scientific Advisory Board with Leading Experts in Liver Fibrosis
Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, has announced the appointment of two renowned experts in liver fibrosis, Dr. Scott Friedman and Dr. Ira Tabas, to its Scientific Advisory Board (SAB). This expansion of the SAB reflects Carisma’s commitment to advancing transformative treatments for patients.
Dr. Friedman, the Chief Emeritus of Liver Diseases at the Icahn School of Medicine at Mount Sinai, is recognized for his pioneering research into the underlying causes of fibrosis associated with chronic liver disease. His groundbreaking work on the hepatic stellate cell, a key cell type responsible for scar production in the liver, has significantly contributed to the understanding of liver fibrosis. With over 300 peer-reviewed publications and extensive experience mentoring students and fellows, Dr. Friedman brings a wealth of knowledge to Carisma’s scientific endeavors.
Dr. Tabas, the Richard J. Stock Professor and Vice-Chair of Research in the Department of Medicine at Columbia University, has made significant contributions to the study of metabolic dysfunction-associated steatohepatitis (MASH) fibrosis. His research focuses on the interaction between hepatocytes, liver macrophages, and hepatic stellate cells, uncovering key roles for the transcriptional regulator TAZ and the process of macrophages clearing dead hepatocytes in MASH liver. Dr. Tabas’ work has led to patent applications and drug development efforts, making him a valuable addition to Carisma’s Scientific Advisory Board.
Steven Kelly, the President and CEO of Carisma, expressed his excitement about the new appointments, stating, ‘It is an honor to welcome Dr. Friedman and Dr. Tabas to our Scientific Advisory Board. Their extensive experience and groundbreaking research in liver fibrosis will significantly enhance our efforts in developing innovative engineered macrophage therapies for advanced liver disease. We are excited to collaborate with them and benefit from their profound expertise.’
Carisma Therapeutics, headquartered in Philadelphia, PA, is focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies for cancer and other serious diseases. By harnessing the power of engineered macrophages and monocytes, Carisma aims to create comprehensive and differentiated cell therapy solutions that target both the innate and adaptive immune response.
For more information about Carisma Therapeutics and its innovative approach to immunotherapy, please visit www.carismatx.com.